<DOC>
	<DOCNO>NCT00663559</DOCNO>
	<brief_summary>The purpose trial determinate efficacy Sunitinib patient renal cell carcinoma metastasic locally avanced patints candidate inicial curative nefrectomy .</brief_summary>
	<brief_title>Sunitinib Patients With Renal Cells Carcinoma Metastasic Locally Avanced Patients Not Candidates Curative Previous Nefrectomy</brief_title>
	<detailed_description>Study phase II one arm patient renal cell carcinoma .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients must give write informed consent procedure relate study perform . Patients renal clear cell carcinoma metastatic locally advanced , histologically cytologically documented.The patient metastasic disease must condidated curative nefrectomy investigator criterion . Assessable measurable disease accord RECIST criterion . The lesion previosly radiate consider target . Ages equal superior 18 year old . ECOG ≤ 1 Patients life expectancy superior 12 week . Patients adequate organic function , accord follow criterion : 1. . Medular reserve : Neutrophils absolute count≥ 1.5 x 10^9/L Platelets ≥ 100 x 10^9/L Haemoglobin ≥ 9g/dl 2. . Hepatic function : Total bilirubin &lt; 1.5 time superior limit normality ALT AST &lt; 2.5 time superior limit normality ( &lt; 5 time superior limit normality case liver failure due cancer ) 3. . Seric Albumin ≥ 1.5 time superior limit normality 4. . Renal Function : Cleary creatinine &gt; 30ml/min 5. . FEVI &gt; LIN accord ECO MUGA Patients capable accomplish study 's requirement without impediment follow instruction study Pregnant breastfeed woman . Women fertile age must negative result pregnancy test perform 7 day begin administration study medication . Both men woman include study must use adequate contraceptive method . Patients receive sistemic treatment previous metastasic disease . Previous nefrectomy . Mayor Surgery , radiotherapy sistemic therapy receive last 3 week previous inclusion patient study , except paliative radiotherapy upper target lesion . Radiotherapy upper &gt; 25 % bone marrow . Patients participate clinical trial . Patients primary cancer diagnosis thast 3 year , except superficial basaliomas , superficial escamous carcinoma situ cervix carcinoma aducuate treatment . Following event last 12 month previous begin treatment : myocardial infarction , unstable severe angina , coronary/periferic place arterial bypass , congestive cardiac insufficiency , brainvascular accident include transitory ischemia lung embolism . Arterial uncontrolled hypertension controlated drug ( &gt; 150/100 mmHg despite adequate medical treatment ) . Cardiac arrhythmia grade NCI CTCAE ≥2 , auricular fibrillation grade and/or QTc interval &gt; 450mseg men &gt; 470 mseg woman . Actually treatment therapeutic dose acenocumarol ( except low dose deep venous thrombosis ) . Patients present previously know positive serology HIV . Abuse substance , clinical condition , psychological social , may interfere patient 's participation study evaluation study 's result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>renal</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Unresectable and/or metastatic renal cell cancer</keyword>
</DOC>